New Pap guidelines may miss aggressive cancer in young women, study reports

by Serena Gordon, Healthday Reporter
New pap guidelines may miss aggressive cancer in young women: study
One cancer can cause problems in less than two years, but recommended screening is now every three years.

(HealthDay)—Recent changes to cervical cancer screening guidelines that recommend less stringent testing may result in a higher incidence of a particularly aggressive type of cervical cancer in young women, a new study suggests.

When the U.S. guidelines for cervical were first changed in March 2012, the differences were clear-cut: Women could start getting cervical cancer screenings at a later age and an annual for everyone was being replaced with a longer interval between screenings—typically three to five years, as long as no abnormalities showed up in a test.

But the researchers found that the time from a first abnormal Pap test to a diagnosis of this fast-moving cancer, known as adenocarcinoma of the , was 21 months in women under 30 and 29 months for women older than 30.

"Any time national guidelines are changed pretty dramatically, I think it's important to reassess areas that may have been weakened," said study author Dr. Lisa Barroilhet, an assistant professor of gynecologic oncology at the University of Wisconsin in Madison.

"I don't think the new guidelines will cause a rampant of adenocarcinomas, [but] it's important to think about how a cure is obtained, which often involves removing a significant portion of the cervix," Barroilhet said. "If you're in your teens or 20s, you're probably not through with childbearing yet."

Results of the study were released online March 7 and will appear in the April print issue of the journal .

Adenocarcinoma used to be a rarer cancer of the cervix than squamous cell cancers. But because cervical cancer screening is so good at catching squamous , the rate of adenocarcinomas as a proportion of all cervical cancers has been increasing, Barroilhet said. The early form of this cancer is referred to as adenocarcinoma in situ.

Cervical cancers usually are detected through the use of the Pap screening test, which involves collecting cells from the cervix and checking them for any abnormalities. More recently, screening for the human papillomavirus (HPV) also has become part of some cervical cancer screens. The HPV virus is responsible for almost all cervical cancers, according to the U.S. National Cancer Institute.

In general, the new recommendations are:

  • No screening for women under 21.
  • Women between the ages of 21 and 29 should have a Pap test every three years.
  • A Pap test every three years or a combination Pap test along with testing for HPV, for women between the ages of 30 and 65.
  • Screening isn't recommended for women over 65 unless they have a higher risk of or if they haven't gotten regular screenings in the past.
The current study reviewed a decade of a cases of women diagnosed with adenocarcinoma in situ (AIS) at Brigham and Women's Hospital in Boston.

Of the 242 women who were diagnosed with AIS, 208 had shown an abnormality in their Pap test. For two-thirds of those women, their Pap test initially suggested squamous cell changes rather than AIS, according to the study.

are much slower-moving cancers, Barroilhet said. For the women in the study who were eventually diagnosed with AIS, however, the time from their abnormal Pap test to a diagnosis of AIS was 29 months for women older than 30, and just 21 months for those aged 30 and younger.

Seventeen cases occurred in women under 21, and 16 of these women had abnormal Pap tests, according to the study.

Dr. Elizabeth Poyner, a gynecologic oncologist at Lenox Hill Hospital in New York City, said it's particularly important to find these cancers early in women of age, because the treatments that are necessary to save a woman's life may compromise her fertility.

Barroilhet said these findings need to be confirmed in a larger group of women, and with patients from more than just one hospital. She also said she didn't think the current guidelines need to be re-examined due to the new findings.

"I think our were developed thoughtfully and thoroughly," she said. But, she added, this study does show a potential weakness in the guidelines.

Poyner agreed. "This is something we need to have a conversation about," she said. "Will the new guidelines compromise our ability to find adenocarcinoma in situ? Only time will tell for sure, but this is something we need to be concerned about."

Barroilhet added that young can take an important step to protect themselves by getting vaccinated against HPV. The vaccine is recommended at age 12 or 13, but is approved for use in females from the ages of 9 to 26.

"If you get your HPV vaccine, the Pap screen then becomes much less critical," Barroilhet said.

More information: To learn more about the Pap test, visit the U.S. National Cancer Institute.

add to favorites email to friend print save as pdf

Related Stories

Health groups issue cervical cancer screening guidelines

Mar 14, 2012

The American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) have released new guidelines for the prevention and early detection ...

HPV test beats pap long-term: study

Jul 30, 2012

(HealthDay) -- Testing for HPV, the human papillomavirus linked to cervical cancer, can predict which women will stay cancer-free for a decade or more, a new study shows.

Younger women start to follow pap test guidelines: CDC

Jan 03, 2013

(HealthDay)—More young women are following recently revised U.S. guidelines for getting Pap tests—the standard screening for cervical cancer—but many women who have had a total hysterectomy still get ...

Recommended for you

Ob-gyn guidance issued for young cancer patient concerns

Jul 25, 2014

(HealthDay)—Young cancer patients and survivors may have gynecologic concerns, which should be managed before, during, and after treatment, according to a Committee Opinion published in the August issue ...

Common blood thinner for pregnant women proven ineffective

Jul 24, 2014

It's a daily injection to the belly for pregnant women at risk of developing blood clots and it's ineffective, according to a clinical trial led by researchers at The Ottawa Hospital and published today by the prestigious ...

Improving life before it begins

Jul 22, 2014

A group of Mexican specialists in fetal medicine have successfully performed over 200 surgeries on unborn babies, inside the womb of the mother. Doctors, grouped under the signature Fetal Medicine Mexico, ...

User comments